Discover open access scientific publications

Search, annotate, share and cite publications

Publications by T. Plesner

Daratumumab, Lenalidomide, and Dexamethasone (Drd) vs Lenalidomide and Dexamethasone (Rd) in Relapsed or Refractory Multiple Myeloma (Rrmm): Efficacy and Safety Update (Pollux)

Hematological Oncology

English

Related publications

Cost-Effectiveness Analysis of Daratumumab, Lenalidomide, and Dexamethasone (DRD) and Daratumumab, Bortezomib, and Dexamethasone (DVD) Versus Standard of Care in Relapsed or Refractory Multiple Myeloma (RRMM)

English

Daratumumab, Bortezomib and Dexamethasone (Dvd) vs Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma (Rrmm): Efficacy and Safety Update (Castor)

Hematological Oncology

English

Efficacy and Safety of Long-Term Treatment With Lenalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

English

Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Relapsed or Refractory Multiple Myeloma: A Phase 1b Study

American Journal of Hematology

Hematology

2019

English

Low-Dose Lenalidomide and Dexamethasone Combination Treatment in Elderly Patients With Relapsed and Refractory Multiple Myeloma

Hematology

2016

English

Pcn73 - Budget Impact of Ixazomib in Combination With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma in Russia

English

Phase II Trial to Investigate Efficacy and Safety of Bendamustine, Dexamethasone and Thalidomide in Relapsed or Refractory Multiple Myeloma Patients After Treatment With Lenalidomide and Bortezomib

British Journal of Haematology

Hematology

2018

English

Disseminated Cryptococcosis in a Patient With Multiple Myeloma Treated With Daratumumab, Lenalidomide, and Dexamethasone

Internal Medicine

Medicine

2019

English

Pcn173 - Cost-Effectiveness of New Triplet Combinations With Lenalidomide and Dexamethasone for Patients With Relapsed or Refractory Multiple Myeloma

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by T. Plesner

Daratumumab, Lenalidomide, and Dexamethasone (Drd) vs Lenalidomide and Dexamethasone (Rd) in Relapsed or Refractory Multiple Myeloma (Rrmm): Efficacy and Safety Update (Pollux)

Related publications

Cost-Effectiveness Analysis of Daratumumab, Lenalidomide, and Dexamethasone (DRD) and Daratumumab, Bortezomib, and Dexamethasone (DVD) Versus Standard of Care in Relapsed or Refractory Multiple Myeloma (RRMM)

Daratumumab, Bortezomib and Dexamethasone (Dvd) vs Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma (Rrmm): Efficacy and Safety Update (Castor)

Efficacy and Safety of Long-Term Treatment With Lenalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Relapsed or Refractory Multiple Myeloma: A Phase 1b Study

Low-Dose Lenalidomide and Dexamethasone Combination Treatment in Elderly Patients With Relapsed and Refractory Multiple Myeloma

Pcn73 - Budget Impact of Ixazomib in Combination With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma in Russia

Phase II Trial to Investigate Efficacy and Safety of Bendamustine, Dexamethasone and Thalidomide in Relapsed or Refractory Multiple Myeloma Patients After Treatment With Lenalidomide and Bortezomib

Disseminated Cryptococcosis in a Patient With Multiple Myeloma Treated With Daratumumab, Lenalidomide, and Dexamethasone

Pcn173 - Cost-Effectiveness of New Triplet Combinations With Lenalidomide and Dexamethasone for Patients With Relapsed or Refractory Multiple Myeloma